Form 4: Zura Bio Ltd: Chief Legal Officer Kim Davis Reports Stock Option Grant
SEC Form 4 Filing
Kim Davis, Chief Legal Officer of Zura Bio Ltd, reports the acquisition of stock options for 488,800 Class A Ordinary Shares.
Summary
- Kim Davis, the Chief Legal Officer of Zura Bio Ltd, filed a Form 4 with the SEC on March 3, 2025.
- The filing reports the grant of employee share options to Davis on February 27, 2025, for 488,800 Class A Ordinary Shares at an exercise price of $1.20.
- The options vest over time, starting with one-fourth on February 27, 2026, and the remainder in equal quarterly installments thereafter, contingent upon continuous service.
- Davis also granted power of attorney to Lindsey McClelland of Zura Bio Limited to execute and file SEC forms on their behalf.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.
Positives
- The grant of stock options to the Chief Legal Officer aligns their interests with those of the shareholders.
- The vesting schedule incentivizes continued service with the company.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common practice in the biotech industry to incentivize and retain key personnel. This filing is a routine disclosure related to executive compensation.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotechnology sector.
- Vesting schedules, such as the one described in the filing, are typical and designed to incentivize long-term commitment.
- Comparable companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
Stakeholder Impact
- Shareholders may view the option grant as a positive incentive for the Chief Legal Officer to contribute to the company's long-term success.
- Employees may see this as a positive sign of investment in the leadership team.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Date of the option grant. |
| 02/27/2026 | First vesting date for the options (1/4th of the shares). |
| 03/03/2025 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.